Pollen Allergy Pipeline Insights Study 2016 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/dh7gkz/pollen) has announced the addition of the "Pollen Allergy-Pipeline Insights, 2016" report to their offering.

Pollen Allergy Infection-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Pollen Allergy Infection. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Pollen Allergy Infection.

The report also assesses the Pollen Allergy Infection therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Pollen Allergy Infection
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Pollen Allergy Infection pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Pollen Allergy Infection and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Pollen Allergy Infection Overview
  2. Pollen Allergy Infection Pipeline Therapeutics
  3. Pollen Allergy Infection Therapeutics under Development by Companies
  4. Pollen Allergy Infection Filed and Phase III Products
  5. Comparative Analysis
  6. Pollen Allergy Infection Phase II Products
  7. Comparative Analysis
  8. Pollen Allergy Infection Phase I and IND Filed Products
  9. Comparative Analysis
  10. Pollen Allergy Infection Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Pollen Allergy Infection - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Pollen Allergy Infection - Discontinued Products
  19. Pollen Allergy Infection - Dormant Products
  20. Companies Involved in Therapeutics Development for Pollen Allergy Infection

For more information visit http://www.researchandmarkets.com/research/dh7gkz/pollen

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals